India, April 11 -- The U.S. Food and Drug Administration has announced a plan to replace animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods.
The plan is in line with the agency's efforts to modernize regulatory science as technology advances, and follows the demand by Congress and the scientific community over the years for more human-relevant testing methods.
The health regulator noted that the proposed elimination of animal testing is designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation, lowering research and development or R&D costs, and eventually drug prices.
According to the FDA Commissioner Martin Mak...